The success of Viagra initially drove a surge for pharma, but recent shifts present a uncertain scenario for investors. Off-patent versions are eating into revenue, and continued patent challenges add more complexity https://kalefnrw761708.digiblogbox.com/65575661/the-blue-pill-and-pharma-a-risky-investment